186 related articles for article (PubMed ID: 37476584)
1. Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.
Utispan K; Thuwajit P; Abiko Y; Charngkaew K; Paupairoj A; Chau-in S; Thuwajit C
Mol Cancer; 2010 Jan; 9():13. PubMed ID: 20096135
[TBL] [Abstract][Full Text] [Related]
4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation.
Chen Y; Xu X; Wang Y; Zhang Y; Zhou T; Jiang W; Wang Z; Chang J; Liu S; Chen R; Shan J; Wang J; Wang Y; Li C; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):265. PubMed ID: 37821935
[TBL] [Abstract][Full Text] [Related]
6. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
[TBL] [Abstract][Full Text] [Related]
7. RNA-sequencing reveals the expression profiles of tsRNAs and their potential carcinogenic role in cholangiocarcinoma.
Li YK; Yan LR; Wang A; Jiang LY; Xu Q; Wang BG
J Clin Lab Anal; 2022 Oct; 36(10):e24694. PubMed ID: 36098712
[TBL] [Abstract][Full Text] [Related]
8. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
[TBL] [Abstract][Full Text] [Related]
10. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
[TBL] [Abstract][Full Text] [Related]
11. CHST4 might promote the malignancy of cholangiocarcinoma.
Zhang G; Liu X; Jian A; Zheng K; Wang H; Hao J; Zhi S; Zhang X
PLoS One; 2022; 17(3):e0265069. PubMed ID: 35294478
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of Novel Biomarkers and Potential Targeted Drugs in Cholangiocarcinoma: Bioinformatics, Virtual Screening, and Biological Evaluation.
Wang J; Zhu W; Tu J; Zheng Y
J Microbiol Biotechnol; 2022 Oct; 32(10):1262-1274. PubMed ID: 36224755
[TBL] [Abstract][Full Text] [Related]
13. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
14. Expressional and prognostic value of HPCAL1 in cholangiocarcinoma via integrated bioinformatics analyses and experiments.
Ma M; Zeng G; Li J; Liang J; Huang L; Chen J; Lai J
Cancer Med; 2023 Jan; 12(1):824-836. PubMed ID: 35645147
[TBL] [Abstract][Full Text] [Related]
15. The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma.
Correnti M; Cappon A; Pastore M; Piombanti B; Lori G; Oliveira DVPN; Munoz-Garrido P; Lewinska M; Andersen JB; Coulouarn C; Sulpice L; Peraldo Neia C; Cavalloni G; Quarta S; Biasiolo A; Fassan M; Ramazzotti M; Parri M; Recalcati S; di Tommaso L; Campani C; Invernizzi P; Torzilli G; Marra F; Pontisso P; Raggi C
Liver Int; 2022 Jan; 42(1):233-248. PubMed ID: 34478594
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses.
Wu HY; Xia S; Liu AG; Wei MD; Chen ZB; Li YX; He Y; Liao MJ; Hu QP; Pan SL
Mol Med Rep; 2019 Dec; 20(6):5002-5020. PubMed ID: 31638221
[TBL] [Abstract][Full Text] [Related]
17. Serum KIAA1199 is an advanced-stage prognostic biomarker and metastatic oncogene in cholangiocarcinoma.
Zhai X; Wang W; Ma Y; Zeng Y; Dou D; Fan H; Song J; Yu X; Xin D; Du G; Jiang Z; Zhang H; Zhang X; Jin B
Aging (Albany NY); 2020 Nov; 12(23):23761-23777. PubMed ID: 33197891
[TBL] [Abstract][Full Text] [Related]
18. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus.
Saengboonmee C; Sorin S; Sangkhamanon S; Chomphoo S; Indramanee S; Seubwai W; Thithuan K; Chiu CF; Okada S; Gingras MC; Wongkham S
World J Gastroenterol; 2023 Jul; 29(28):4416-4432. PubMed ID: 37576707
[TBL] [Abstract][Full Text] [Related]
19. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.
Ma S; Ma Y; Qi F; Lei J; Chen F; Sun W; Wang D; Zhou S; Liu Z; Lu Z; Zhang D
World J Surg Oncol; 2023 Sep; 21(1):293. PubMed ID: 37718459
[TBL] [Abstract][Full Text] [Related]
20. Dense GM-CSFR
Saranaruk P; Waraasawapati S; Chamgramol Y; Sawanyawisuth K; Paungpan N; Somphud N; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
PeerJ; 2023; 11():e14883. PubMed ID: 36883059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
